Q2 2021 Results - Reimagining Medicine
Participants
Financial review
Conclusion
Appendix
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Novartis pipeline in Phase 3
References
Innovation: Clinical trials
6 lead indications
Lead indication
Oncology
Code
Name
AAA617
177 Lu-PSMA-617
Mechanism
Indication(s)
Metastatic castration-resistant prostate cancer (mCRPC)
Radioligand therapy target PSMA mCRPC, pre-taxane
Metastatic hormone sensitive prostate cancer (mHSPC)
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
AAA6011)
LutatheraⓇ
ABL001
asciminib
BCR-ABL inhibitor
ACZ885
canakinumab
IL-1b inhibitor
BYL719
CTL019
Piqray®
KymriahⓇ
PI3Ka inhibitor
CD19 CAR-T
tumors (GEP-NET 1L G3)
Neuroscience
Code
AMG334 AimovigⓇ
Name
BAF312 Mayzent®
Respiratory Disease
Code Name
IGE025 XolairⓇ
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Mechanism
IgE inhibitor
Indication(s)
Food allergy
Auto-injector
Cardiovascular, Renal, Metabolism
Chronic myeloid leukemia, 1st line
Non-small cell lung cancer (NSCLC), 1L
HER2+ adv BC
NSCLC, adjuvant
Triple negative breast cancer Ovarian cancer
Code Name
KJX839 Leqvio®
LCZ696 EntrestoⓇ
LNP023 Iptacopan
BRAF inhibitor + MEK inhibitor
Thrombopoietin receptor (TPO-R)
agonist
DRB436
ETB115
Tafinlar + Mekinist
PromactaⓇ
LEE011
Kisqali®
CDK4/6 Inhibitor
MBG453
Sabatolimab
TIM3 antagonist
r/r Follicular lymphoma
1L high risk acute lymphocytic leukaemia, pediatrics & young adults
Relapsed/refractory aggressive non-Hodgkin's lymphoma
Thyroid cancer
Radiation sickness syndrome
HR+/HER2- BC (adj)
Myelodysplastic syndrome
2L ESCC
1L Nasopharyngeal Carcinoma
1L ESCC
1L Hepatocellular Carcinoma
TQJ230 Pelacarsen
Non-small cell lung cancer
1L Gastric cancer
Localized ESCC
Biosimilars
Code
1L Small Cell Lung Cancer
Name
GP2411 denosumab
SOK583 aflibercept
1L Bladder Urothelial Cell Carcinoma
VDT482
tislelizumab
PD1 inhibitor
Mechanism
siRNA (regulation of LDL-C)
Angiotensin receptor/neprilysin
inhibitor
CFB inhibitor
ASO targeting Lp(a)
Indication(s)
CVRR-LDLC
Hyperlipidemia, pediatrics
Congestive heart failure, pediatrics²)
Paroxysmal nocturnal haemoglobinuria
IgA nephropathy
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Mechanism
anti RANKL mAb
VEGF inhibitor
Indication(s)
Denosumab BioS
Ophthalmology indication (as originator)
Immunology, Hepatology, Dermatology
Code
Name
AIN457
Cosentyx®
QGE031 ligelizumab
Mechanism
IL17A inhibitor
IgE inhibitor
Indication(s)
Lupus Nephritis
AS H2H Hidradenitis suppurativa
Psoriatic arthritis (IV formulation)
Ankylosing spondylitis (IV formulation)
Chronic spontaneous urticaria
Chronic inducible urticarial (CINDU)
1. 177 Lu-dotatate in US. 2. Approved in US.
3. Under evaluation.
51 Investor Relations | Q2 2021 Results
Ophthalmology
Code
Name
RTH258 BeovuⓇ
Mechanism
VEGF inhibitor
Global Health
Food allergy
Code
COA566
Name
Coartem®
Mechanism
Indication(s)
Diabetic retinopathy
Retinal vein occlusion³
Diabetic macular edemal
Indication(s)
Malaria, uncomplicated (<5kg patients)
U NOVARTIS | Reimagining MedicineView entire presentation